polarityTE

SkinTE® Met Primary and Secondary Endpoints in Multicenter, Randomized Controlled Trial in Venous Leg Ulcers

PolarityTE announced results from a multi-center randomized controlled trial evaluating treatment of Venous Leg Ulcers (VLU) with its…
PolarityTE Announces Allowance of Fourth U.S. Patent

PolarityTE, Inc. announced the U.S. Patent and Trademark Office (USPTO) recently issued a Notice of Allowance for U.S.…
PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

PolarityTE, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND)…
PolarityTE Announces Submission of Complete Response to FDA’s Clinical Hold Correspondence for SkinTE® Investigational New Drug Application

PolarityTE has submitted its complete response to the U.S. FDA clinical hold correspondence regarding its Investigational New Drug…
PolarityTE Reports Third Quarter Financial Results and Provides Business Update

PolarityTE, Inc. recently provided a business update and reported financial results for the three and nine-month periods ended…
PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE®

PolarityTE, Inc. today provided an update regarding correspondence from the U.S. Food and Drug Administration (FDA) related to its…

Call to Action